Xiaoming Jia1, Payal Kohli2, Salim S Virani3,4,5. 1. Section of Cardiovascular Research, Department of Medicine, Baylor College of Medicine, Houston, TX, USA. 2. Heart and Vascular Institute of Colorado, SCL Health, Denver, CO, USA. 3. Section of Cardiovascular Research, Department of Medicine, Baylor College of Medicine, Houston, TX, USA. virani@bcm.edu. 4. Health Policy, Quality and Informatics Program, Michael E. DeBakey Veterans Affairs Medical Center Health Services Research and Development Center for Innovations, Houston, TX, USA. virani@bcm.edu. 5. Health Services Research and Development, Michael E. DeBakey Veterans Affairs Medical Center, 2002 Holcombe Boulevard, Houston, TX, 77030, USA. virani@bcm.edu.
Abstract
PURPOSE OF REVIEW: Omega-3 fatty acids (ω-3 FA) are among the most well-recognized health supplements but their cardiovascular benefits have long been controversial owing to inconsistent results from previous cardiovascular outcomes trials (CVOT). In this article, we provide a short review of existing literature followed by recent randomized clinical trial data, with a discussion of the potential clinical implications of these new findings. RECENT FINDINGS: Data from the randomized, controlled trial REDUCE-IT, when viewed within the context of other recently published trials ASCEND and VITAL, add to a growing body of evidence on the use of ω-3 FA therapies in the treatment of atherosclerotic cardiovascular disease (ASCVD). Given the different formulations, dosages, and patient populations studied, CVOTs of ω-3 FA have provided valuable insight into the use of these agents in cardioprotection. Current data suggest that higher dosages of pure eicosapentaenoic acid ω-3 FA formulations provide additional benefit in reduction of ASCVD events.
PURPOSE OF REVIEW: Omega-3 fatty acids (ω-3 FA) are among the most well-recognized health supplements but their cardiovascular benefits have long been controversial owing to inconsistent results from previous cardiovascular outcomes trials (CVOT). In this article, we provide a short review of existing literature followed by recent randomized clinical trial data, with a discussion of the potential clinical implications of these new findings. RECENT FINDINGS: Data from the randomized, controlled trial REDUCE-IT, when viewed within the context of other recently published trials ASCEND and VITAL, add to a growing body of evidence on the use of ω-3 FA therapies in the treatment of atherosclerotic cardiovascular disease (ASCVD). Given the different formulations, dosages, and patient populations studied, CVOTs of ω-3 FA have provided valuable insight into the use of these agents in cardioprotection. Current data suggest that higher dosages of pure eicosapentaenoic acid ω-3 FA formulations provide additional benefit in reduction of ASCVD events.
Authors: Deepak L Bhatt; P Gabriel Steg; Michael Miller; Eliot A Brinton; Terry A Jacobson; Steven B Ketchum; Ralph T Doyle; Rebecca A Juliano; Lixia Jiao; Craig Granowitz; Jean-Claude Tardif; Christie M Ballantyne Journal: N Engl J Med Date: 2018-11-10 Impact factor: 91.245
Authors: Bernhard Rauch; Rudolf Schiele; Steffen Schneider; Frank Diller; Norbert Victor; Helmut Gohlke; Martin Gottwik; Gerhard Steinbeck; Ulrike Del Castillo; Rudolf Sack; Heinrich Worth; Hugo Katus; Wilhelm Spitzer; Georg Sabin; Jochen Senges Journal: Circulation Date: 2010-11-08 Impact factor: 29.690
Authors: R Preston Mason; Robert F Jacob; Sandeep Shrivastava; Samuel C R Sherratt; Amitabha Chattopadhyay Journal: Biochim Biophys Acta Date: 2016-10-05
Authors: Marc S Sabatine; Robert P Giugliano; Anthony C Keech; Narimon Honarpour; Stephen D Wiviott; Sabina A Murphy; Julia F Kuder; Huei Wang; Thomas Liu; Scott M Wasserman; Peter S Sever; Terje R Pedersen Journal: N Engl J Med Date: 2017-03-17 Impact factor: 91.245
Authors: Barry London; Christine Albert; Mark E Anderson; Wayne R Giles; David R Van Wagoner; Ethan Balk; George E Billman; Mei Chung; William Lands; Alexander Leaf; John McAnulty; Jeffrey R Martens; Rebecca B Costello; David A Lathrop Journal: Circulation Date: 2007-09-04 Impact factor: 29.690
Authors: J Thomas Brenna; Norman Salem; Andrew J Sinclair; Stephen C Cunnane Journal: Prostaglandins Leukot Essent Fatty Acids Date: 2009-03-09 Impact factor: 4.006
Authors: Mahmoud Al Rifai; Xiaoming Jia; Mouaz H Al-Mallah; Michael D Miedema; Seth S Martin; Salim S Virani Journal: Curr Atheroscler Rep Date: 2019-05-24 Impact factor: 5.113